Competitive Technologies (NYSE Amex: CTT) announced yesterday (April 14) that the long- awaited open Phase II clinical study on the use of CTT's Calmare(NYSE:R) pain therapy with patients suffering from Chemotherapy-Induced Peripheral Neurapathy (CIPN) will be publlished in a medical journal.The company will announce which medical journal and which issue in the next few weeks. A peer-reviewed study is deemed by medical professionals to be of sufficient interest and significance to warrant being published for the broader medical community--a very encouraging sign that CTT's technology showed benefits in treating patients with CIPN.
The study was conducted by Dr.Thomas Smith, Endowed Professor for Palliative Care Research and Medical Director for the Thomas Palliative Care Unit at Massey Cancer Center at the University of Virginia, and Patrick Coyne, Clinical Director of the Thomas Palliative Care Services at Massey Cancer Center.
CTT's Calmare(R) pain therapy medical device, a non-invasive treatment for chronic and cancer pain neuropathies reisistant to standard drug therapy programs, was the subject of the Phase II study which was initiated June 2009 . The last of the patients in the study received the standard 10-day treatment protocol in late November 2009.
From the April 14 Press release: "The study examined the device's effect on pain associated with CIPN that can produce sharp pains in the hands and feet of cancer patients who are undergoing chemotherapy. This debilitating pain affects about 30 to 40 percent of cancer patients treated with chemotherapy ((editor's highlight) and typically develops into a classic stocking-and-glove pain that can last for many years." In other words, CIPN could be a huge market for CTT.
Disclosure: Long CTT